BEIJING, China: The Chinese government introduced a volume-based procurement (VBP) policy in November 2018 in the pharmaceutical industry, and this was later expanded in 2019 to include medical devices sold in China. The primary object of VBP is to reduce the average selling price (ASP) of items in order to make drugs and medical devices more accessible for the entire Chinese population; however, what impact is VBP expected to have on the wider dental implant market in the Asia Pacific region between 2024 and 2030?